Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC)
with a poor prognosis. Current treatment options are limited to surgery, adjuvant …

Breast cancer is the most common cancer worldwide. The occurrence of breast cancer is
associated with many risk factors, including genetic and hereditary predisposition. Breast …

PURPOSE To develop guideline recommendations concerning optimal neoadjuvant therapy
for breast cancer. METHODS ASCO convened an Expert Panel to conduct a systematic …

Breast cancer (BC) is the most frequent cancer diagnosed in women worldwide. This
heterogeneous disease can be classified into four molecular subtypes (luminal A, luminal B …

Purpose: While various studies have highlighted the prognostic significance of pathologic
complete response (pCR) after neoadjuvant chemotherapy (NAT), the impact of additional …

In 2018, the predicted number of new breast cancers in 28 European Union (EU) countries
was 404 920, with estimated age-adjusted annual incidence of breast cancer of 144.9/100 …

Background Previous trials showed promising antitumor activity and an acceptable safety
profile associated with pembrolizumab in patients with early triple-negative breast cancer …

Abstract Background The 16th St. Gallen International Breast Cancer Conference 2019 in
Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies …

Breast cancer is the most frequently diagnosed cancer in women and ranks second among
causes for cancer related death in women. Evidence in literature has shown that the past …

Background Primary analyses of the phase III BrighTNess trial showed addition of
carboplatin with/without veliparib to neoadjuvant chemotherapy significantly improved …